M. Kelly Seo (PhD) is Research Associate in Health Economics at the University of Cambridge for the Cambridge Research Methods Hub (CRMH) (https://www.phpc.cam.ac.uk/pcu/research/research-groups/crmh). She is an experienced health economist, having worked for international organisations (International Labour Organisation (ILO, Geneva) and the International Vaccine Institute (IVI, Seoul)) and HEOR consultancies. She holds a PhD in health economics from the London School of Hygiene and Tropical Medicine (LSHTM). Her PhD thesis was on economic evaluations of companion biomarkers for targeted therapies in cancer. She also holds an MSc in health policy, planning and financing from the London School of Economics (LSE) and LSHTM.
Kelly’s research interests are primarily in the cost-effectiveness of interventions to improve public health across a range of health technologies, disease areas, and population groups. Her research areas include:
• Economic evaluations/Decision-analytic modelling
• Health technology assessment (HTA).
• Survival analysis.
• Care pathway analysis.
• Value of information analysis.
• Systematic literature review and meta-analysis.
Luis ABD, Seo MK, 2022, Reply to comment on “Demonstrating the value of cancer biomarkers at the population” REPLY, EUROPEAN JOURNAL OF HEALTH ECONOMICS, Vol: 23, Pages: 757-758, ISSN: 1618-7598
Seo MK, Strong M, 2021, A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper., Pharmacoeconomics, Vol: 39, Pages: 1373-1381
Seo MK, Cairns J, 2021, How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review., BMC cancer, Vol: 21, ISSN: 1471-2407
Micocci M, Gordon AL, Seo MK, Allen AJ, Davies K, Lasserson D, Thompson C, Spilsbury K, Akrill C, Heath R, Astle A, Sharpe C, Perera R, Hayward G, Buckle Pet al., 2021, Is point-of-care testing feasible and safe in care homes in England? An exploratory usability and accuracy evaluation of a point-of-care polymerase chain reaction test for SARS-CoV-2, Age and Ageing, Vol: 50, Pages: 1464-1472, ISSN: 0002-0729
Luis ABD, Seo MK, 2021, Has the development of cancer biomarkers to guide treatment improved health outcomes?, EUROPEAN JOURNAL OF HEALTH ECONOMICS, Vol: 22, Pages: 789-810, ISSN: 1618-7598
Seo MK, Straume O, Akslen LA, Cairns Jet al., 2020, HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?, PHARMACOECONOMICS-OPEN, Vol: 4, Pages: 529-539, ISSN: 2509-4262
Seo MK, 2019, How are we assessing the value for money of cancer biomarkers in economic evaluations?, Value in Health, ISPOR Europe 2019
Seo MK, 2019, Pricing and reimbursement, and market access of therapeutic materials (medical devices/diagnostics/biomarkers) in South Korea, Value in Health, ISPOR Europe 2019
Seo MK, Cairns J, 2018, Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer., PLoS One, Vol: 13, Pages: 1-23, ISSN: 1932-6203
Blanchard A, Wik E, Seo MK, Cairns J, Tranvåg E, Norheim OF, Fleck LM, Blasimme A, Engen C, Strand Ret al., 2017, Cancer Biomarkers Ethics, Economics and Society, Publisher: Megaloceros Forlag, ISBN: 9788291851044
Seo MK, 2017, Economic evaluations of cancer biomarkers for targeted therapies: practices, challenges, and policy implications, Cancer biomarkers: ethics, economics and society, Editors: Blanchard, Strand, Publisher: Megaloceros Press, 2017. p.25-38
Seo MK, Baker P, Karen N-LN, 2014, Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets, MALARIA JOURNAL, Vol: 13, ISSN: 1475-2875